PRKAA1 and prostate cancer: Thus, auraptene-induced AMPK activation apparently suppresses the cell growth of prostate cancer cells via at least three mechanisms, i.e., by inhibiting lipid metabolism, AR, and the mTOR/S6 kinase pathway.